Addition of Dexmedetomidine to Standard Sedation Regimens After Cardiac Surgery: An Outcomes Analysis
| Autor: | Judith Jacobi, Anne-Marie Sesti, Joseph F. Dasta, Trent McLaughlin |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Midazolam Sedation Lorazepam law.invention law Intensive care Outcome Assessment Health Care medicine Humans Hypnotics and Sedatives Pharmacology (medical) Cardiac Surgical Procedures Dexmedetomidine Propofol Aged Retrospective Studies business.industry Retrospective cohort study Length of Stay Middle Aged Intensive care unit Hospitals Intensive Care Units Anesthesia Cohort Drug Therapy Combination Female medicine.symptom business medicine.drug |
| Zdroj: | Pharmacotherapy. 26:798-805 |
| ISSN: | 0277-0008 |
| DOI: | 10.1592/phco.26.6.798 |
| Popis: | STUDY OBJECTIVE To characterize inpatient use of intravenous sedatives in the real-world setting, and to evaluate clinical and economic outcomes when dexmedetomidine was used with midazolam and propofol for select cardiovascular procedures. DESIGN 12-month retrospective analysis. DATA SOURCE An administrative claims database of operational data from a nationally representative sample of 250 medical and surgical hospitals. PATIENTS Patients who received midazolam plus propofol (9996 patients) or dexmedetomidine, midazolam, plus propofol (356 patients) after cardiac valve or vessel surgery. MEASUREMENTS AND MAIN RESULTS The source of patient demographics (e.g., age, sex, Charlson Comorbidity Index) and outcomes (e.g., charges, length of stay, mortality rate) was the hospital billing claim form. Patients in the dexmedetomidine-midazolam-propofol cohort tended to be younger and male and to have fewer comorbidities than those midazolam-propofol cohort. The primary outcomes for the three-drug cohort showed significant reductions in total charges/patient (approximately $18,000, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text